

## Ammonia

## Order information

REF	CONTENT	Analyzer(s) on which <b>cobas c</b> pack(s) can be used
2076682 322	Ammonia 150 tests	System-ID 07 6668 2
20751995 190	Ammonia/Ethanol/CO2 Calibrator (2 x 4 mL)	Code 688
20752401 190	Ammonia/Ethanol/CO2 Control Normal (5 x 4 mL)	Code 100
20753009 190	Ammonia/Ethanol/CO2 Control Abnormal (5 x 4 mL)	Code 101

## English

## System information

For **cobas c** 311/501 analyzers:

**NH3L**: ACN 478

For **cobas c** 502 analyzer:

**NH3L**: ACN 8478

## Intended use

Enzymatic in vitro test for the quantitative determination of ammonia in human plasma on Roche/Hitachi **cobas c** systems.

Summary<sup>1</sup>

Ammonia is generated primarily in the gastrointestinal tract by metabolism of nitrogenous compounds. An excess of ammonia can be toxic to the central nervous system. The Krebs-Henseleit urea cycle provides a means of disposal of ammonia by metabolizing ammonia to urea in the liver.

Hyperammonemia in infants can be caused by inherited deficiencies of the urea cycle enzymes or acquired through acute (as in Reye's syndrome) or chronic (as in cirrhosis) liver disease. In adults, elevated ammonia levels can aid in diagnosis of liver failure or hepatic encephalopathy from advanced liver diseases such as viral hepatitis or cirrhosis.

## Test principle

Enzymatic method, with glutamate dehydrogenase.<sup>2,3</sup>

Glutamate dehydrogenase (GLDH) catalyzes the reductive amination of 2-oxoglutarate with  $\text{NH}_4^+$  and NADPH to form glutamate and  $\text{NADP}^+$ .

GLDH



The concentration of the  $\text{NADP}^+$  formed is directly proportional to the ammonia concentration. It is determined by measuring the decrease in absorbance.

## Reagents - working solutions

**R1** BICINE<sup>a)</sup> buffer: 330 mmol/L, pH 8.3; GLDH (microbial):  $\geq 234 \mu\text{kat/L}$ ; 2-oxoglutarate: 50 mmol/L; detergent; preservative; nonreactive stabilizer

**R3** NADPH:  $\geq 1.0 \text{ mmol/L}$ ; preservative; nonreactive buffer

a) BICINE = N,N-bis(2-hydroxyethyl)-glycine

R1 is in position A and R3 is in position B.

## Precautions and warnings

For in vitro diagnostic use.

Exercise the normal precautions required for handling all laboratory reagents.

Disposal of all waste material should be in accordance with local guidelines. Safety data sheet available for professional user on request.

## Reagent handling

Unscrew only the grey coloured R3 screw cap using the Open/Close tool (GMMI no. 04857933-190). Keep the screw cap. Prevent it from any contamination. Place the reagent cassette in an environment which is free from cigarette smoke,  $\text{NH}_3$  containing cleaners, and exhaust fumes of any kind. During storage of the cassette at room temperature ensure that it is securely stored so that it doesn't fall over. The cassette must not be covered during the storage at room temperature. Prevent the cassette from debris of any kind. Protect open cassette from sun light, do not store it at the window. After 24 h storage, re-screw the same grey screw cap on the R3 bottle. Mix cassette gently avoiding foam. Load the cassette into the instrument.

## Storage and stability

## NH3L

Shelf life at 2-8 °C:

See expiration date on **cobas c** pack label.

On-board in use and refrigerated on the analyzer: 8 weeks

## Specimen collection and preparation

For specimen collection and preparation only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable.  $\text{K}_2\text{-EDTA}$  plasma (free from hemolysis and lipemia)

## IMPORTANT

Do not use plasma prepared with other anticoagulants.

Do not use serum since ammonia can be generated during clotting.

Collect blood from stasis-free vein of fasting patient. Smoking should be avoided prior to sampling. Tubes should be filled completely and kept tightly stoppered at all times. Place immediately on ice and centrifuge, preferably at 4 °C. Perform analysis within 20 to 30 minutes of venipuncture.

Avoid contamination of samples by ammonia from smoking or traffic in laboratory or patient's room, glassware, or water.

Ammonia concentrations can increase in vitro due to breakdown of nitrogen-containing plasma components. One known source of spontaneous ammonia formation is an increased  $\gamma$ -glutamyltransferase activity leading to decomposition of glutamine.<sup>3</sup>

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

## Materials provided

See "Reagents – working solutions" section for reagents.

## Materials required (but not provided)

- See "Order information" section
- General laboratory equipment

## Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

The performance of applications not validated by Roche is not warranted and must be defined by the user.

## Application for plasma

## cobas c 311 test definition

Assay type	2-Point End
Reaction time / Assay points	10 / 25-57
Wavelength (sub/main)	700/340 nm
Reaction direction	Decrease
Units	$\mu\text{mol/L}$ ( $\mu\text{g/dL}$ )
Reagent pipetting	Diluent ( $\text{H}_2\text{O}$ )
R1	40 $\mu\text{L}$ 32 $\mu\text{L}$

## Ammonia

R3	20 µL	20 µL
<i>Sample volumes</i>	<i>Sample</i>	<i>Sample dilution</i>
		Sample      Diluent (H <sub>2</sub> O)
Normal	20 µL	–
Decreased	10 µL	–
Increased	20 µL	–

**cobas c 501/502 test definition**

Assay type	2-Point End		
Reaction time / Assay points	10 / 36-70		
Wavelength (sub/main)	700/340 nm		
Reaction direction	Decrease		
Units	μmol/L (μg/dL)		
Reagent pipetting	Diluent (H <sub>2</sub> O)		
R1	40 μL	32 μL	
R3	20 μL	20 μL	
<i>Sample volumes</i>	<i>Sample</i>	<i>Sample dilution</i>	
		<i>Sample</i>	Diluent (H <sub>2</sub> O)
Normal	20 μL	—	—
Decreased	10 μL	—	—
Increased	20 μL	—	—

**Calibration**

Calibrators	S1: H <sub>2</sub> O S2: Ammonia/Ethanol/CO <sub>2</sub> Calibrator
Calibration mode	Linear
Calibration frequency	2-point calibration - after <b>cobas c</b> pack change - blank re-calibration automatically every 3 days - as required following quality control procedures

Traceability: This method has been standardized against a primary standard.

**Quality control**

For quality control, use control materials as listed in the "Order information" section.

In addition, other suitable control material can be used.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

**Calculation**

Roche/Hitachi **cobas c** systems automatically calculate the analyte concentration of each sample.

Conversion factor:                      µmol/L x 1.703 = µg/dL

**Limitations - interference**

Criterion: Recovery within ± 10 % of initial values at an ammonia concentration of 50 µmol/L (85 µg/dL).

Icterus:<sup>4</sup> No significant interference up to an I index of 10 for conjugated and 30 for unconjugated bilirubin (approximate conjugated bilirubin concentration: 171 µmol/L (10 mg/dL) and approximate unconjugated bilirubin concentration: 513 µmol/L or 30 mg/dL).

Hemolysis:<sup>4</sup> No significant interference up to an H index of 200 (approximate hemoglobin concentration: 124.2 µmol/L or 200 mg/dL). Contamination with erythrocytes will elevate results, because the analyte level in erythrocytes is higher than in normal plasma. The level of interference may be variable depending on the content of analyte in the lysed erythrocytes.

Lipemia (native):<sup>4</sup> No significant interference up to an L index of 50. There is a poor correlation between the L index (corresponds to turbidity) and triglycerides concentration.

γ-Globulin: γ-Globulin significantly increases the apparent ammonia concentration when 3 g/dL are added to a human plasma pool.

Drugs: No interference was found at therapeutic concentrations using common drug panels.<sup>5,6</sup>

Exceptions: Cefoxitin and Intralipid cause artificially high and low ammonia results respectively at the therapeutic drug level.

Physiological plasma concentrations of Sulfasalazine and Sulfapyridine may lead to false results. Temozolomide at therapeutic concentrations may lead to erroneous results.

In very rare cases, gammopathy, in particular type IgM (Waldenström's macroglobulinemia), may cause unreliable results.<sup>7</sup>

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

**ACTION REQUIRED**

**Special Wash Programming:** The use of special wash steps is mandatory when certain test combinations are run together on Roche/Hitachi **cobas c** systems. The latest version of the carry-over evasion list can be found with the NaOHD/SMS/Multiclean/SCCS or the NaOHD/SMS/SmpCln1+2/SCCS Method Sheets. For further instructions refer to the operator's manual. **cobas c** 502 analyzer: All special wash programming necessary for avoiding carry-over is available via the **cobas** link, manual input is not required.

**Where required, special wash/carry-over evasion programming must be implemented prior to reporting results with this test.**

**Limits and ranges****Measuring range**

10-700 µmol/L (17-1192 µg/dL)

Determine samples having higher concentrations via the rerun function. Dilution of samples via the rerun function is a 1:2 dilution. Results from samples diluted using the rerun function are automatically multiplied by a factor of 2.

**Lower limits of measurement***Lower detection limit of the test*

10 µmol/L (17 µg/dL)

The lower detection limit represents the lowest measurable analyte level that can be distinguished from zero. It is calculated as the value lying three standard deviations above that of the lowest standard (standard 1 + 3 SD, repeatability, n = 21).

**Expected values***EDTA plasma<sup>8</sup>*

Females	11-51 µmol/L	(18.7-86.9 µg/dL)
Males	16-60 µmol/L	(27.2-102 µg/dL)

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

**Specific performance data**

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

**Precision**

Precision was determined using human samples and controls in an internal protocol with repeatability (n = 21) and intermediate precision (3 aliquots per run, 1 run per day, 21 days). The following results were obtained:

Repeatability	Mean	SD	CV
	µmol/L (µg/dL)	µmol/L (µg/dL)	%

**Ammonia**

AEC Control N	60.7 (103)	1.4 (2)	2.3
AEC Control A	202 (344)	2 (3)	0.8
Human plasma 1	28.6 (48.7)	2.5 (4.3)	8.8
Human plasma 2	585 (996)	1 (2)	0.2
<i>Intermediate precision</i>	<i>Mean</i>	<i>SD</i>	<i>CV</i>
	<i>μmol/L (μg/dL)</i>	<i>μmol/L (μg/dL)</i>	<i>%</i>
AEC Control N	56.9 (97.1)	2.8 (4.8)	4.9
AEC Control A	203 (346)	4 (7)	1.8
AEC Control N 1:2 dil.	28.1 (47.7)	2.6 (4.4)	9.4
AEC Calibrator	318 (542)	5 (9)	1.5

**Method comparison**

Ammonia values for human plasma samples obtained on a Roche/Hitachi **cobas c 501** analyzer (y) were compared with those determined on Roche/Hitachi 917/MODULAR P analyzers (x), using the corresponding Roche/Hitachi reagent.

Sample size (n) = 171

Passing/Bablok <sup>9</sup>	Linear regression
$y = 0.996x + 5.11 \mu\text{mol/L}$	$y = 1.007x + 4.06 \mu\text{mol/L}$
$r = 0.970$	$r = 0.999$

The sample concentrations were between 18.1 and 444 μmol/L (30.8 and 756 μg/dL).

**References**

- 1 Balistreri WF, Rej R. Liver function. In: Burtis CA, Ashwood ER, eds. Tietz Fundamentals of Clinical Chemistry. 4th ed. Philadelphia: WB Saunders 1996;539-568.
- 2 Van Anken HC, Schiphorst ME. A kinetic determination of ammonia in plasma. Clin Chim Acta 1974;56:151-157.
- 3 Da Fonseca-Wollheim F. Deamidation of glutamine by increased plasma γ-glutamyltransferase is a source of rapid ammonia formation in blood and plasma of rapid ammonia formation in blood and plasma specimens. Clin Chem 1990;36:1479-1482.
- 4 Glick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-475.
- 5 Breuer J. Report on the Symposium "Drug effects in Clinical Chemistry Methods". Eur J Clin Chem Clin Biochem 1996;34:385-386.
- 6 Sonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. Ann Clin Biochem 2001;38:376-385.
- 7 Bakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention. Clin Chem Lab Med 2007;45(9):1240-1243.
- 8 Da Fonseca-Wollheim F. Direkte Plasmaammoniakbestimmung ohne Enteiweissung. Z Klin Chem Klin Biochem 1973;11:426-431.
- 9 Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem 1988 Nov;26(11):783-790.

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

**Symbols**

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard.



Contents of kit

Volume after reconstitution or mixing

**FOR US CUSTOMERS ONLY: LIMITED WARRANTY**

Roche Diagnostics warrants that this product will meet the specifications stated in the labeling when used in accordance with such labeling and will be free from defects in material and workmanship until the expiration date printed on the label. THIS LIMITED WARRANTY IS IN LIEU OF ANY OTHER WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE. IN NO EVENT SHALL ROCHE DIAGNOSTICS BE LIABLE FOR INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES.

COBAS, COBAS C and MODULAR are trademarks of Roche.

All other product names and trademarks are the property of their respective owners.

Significant additions or changes are indicated by a change bar in the margin.

© 2014, Roche Diagnostics



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim  
www.roche.com

Distribution in USA by:  
Roche Diagnostics, Indianapolis, IN  
US Customer Technical Support 1-800-428-2336

